AI biotech firm Inherent raises £37.2m led by Index Ventures and Radical Ventures
This article covers Inherent, a biotech startup, raising £37.2m in a growth funding round to develop Faraday, a platform of self-improving AI agents aimed at speeding scientific discovery. The development aims to support long-horizon research in biotech and life sciences and is significant for researchers, investors and policymakers tracking AI-driven discovery tools.
Inherent has raised £37.2m in a growth funding round to develop Faraday, a platform of self-improving AI agents aimed at speeding scientific discovery; the raise matters because it signals strong investor appetite for ambitious AI-first approaches to long-horizon problems in biotech and life sciences.
Why it matters
The size of the raise and the profile of the backers mark this as one of the more prominent AI-for-science announcements out of Europe in 2026. Inherent’s founding team includes researchers from DeepMind, Microsoft, and Reka AI, and the company lists a former Biden White House AI policy advisor among its founders. That combination of deep research experience and policy connections positions the company to pursue high-impact scientific targets while navigating regulatory attention that autonomous, self-modifying systems tend to attract.
If Faraday delivers on even a subset of its ambitions, it could change how research labs approach discovery workflows and force incumbent AI research units and large cloud providers to respond. Conversely, the project carries technical and reputational risk: claims about “self-improving” agents require clear benchmarks and independent validation that the announcement does not yet provide.
Inside the product
Faraday is described as a platform that pairs humans with AI agents that iteratively improve themselves to solve hard, open scientific problems rather than being focused on enterprise automation. The stated aim is long-horizon discovery tasks where current methods struggle.
Key unknowns remain. The company has not published architecture details, evaluation methodologies, or peer-reviewed results, so the core technical claims are not yet verifiable. The announcement also did not outline any external oversight, alignment framework, or red‑teaming processes for managing risks associated with self-modifying models.
Who are the investors?
The round was co-led by Index Ventures and Radical Ventures, with participation from NVIDIA Ventures. Index Ventures is a long-established European venture firm; Radical Ventures is known for early-stage AI backing; NVIDIA Ventures typically invests where its hardware and platform partnerships can accelerate compute-heavy projects.
NVIDIA Ventures’ involvement is strategically notable because intensive scientific workloads depend on access to specialised accelerators and infrastructure. The participation of these investors signals both confidence in the team and an expectation that Faraday will require substantial compute and partnerships with cloud and infrastructure providers as it scales.
If you're researching potential backers in this space:
- Explore our list of biotech venture capital firms in the UK
- Browse our directory of biotech angel investors in the UK
Founder perspective
The founding team’s pedigree is a major part of the story. Researchers from top-tier AI labs provide technical credibility, and the presence of a former White House AI policy advisor among the founders — along with Matt Clifford joining as an adviser — suggests the company is proactively positioning itself at the intersection of research and regulation. That stance may open doors to government research collaborations, but it also draws scrutiny from policymakers already working on UK and European AI rules.
The bigger picture
Technically ambitious biotech-focused AI efforts face a tight set of trade-offs: proving scientific value at scale, securing specialised compute, and demonstrating safety and reproducibility. Potential infrastructure partners include specialist compute providers and major cloud platforms, while pharma and biotech firms could become early collaborators or customers if Faraday produces usable, validated outputs.
There is also competitive pressure from incumbents such as DeepMind and other research automation labs building similar agentic tooling. For investors, the raise represents a bet that a research-first, policy-savvy lab can move faster than larger organisations constrained by existing structures.
This deal reflects continuing investor interest in the convergence of AI and biotech across the UK and Europe. Its progress — especially how it demonstrates safety, reproducibility, and measurable scientific impact — will be watched closely by biotech investors, policymakers, and research institutions in the months ahead.
They've invested in Inherent
Get to know these biotech investors
| Investors | Investment Focus | Startup Investments | Round Size | Connect |
|---|---|---|---|---|
InherentScope AIMultiverseAdfinAnkar+8 | ||||
InherentOrbital IndustriesLatent Labs | ||||
 NVIDIA Ventures( ) | Inherent | |||
| All investors | All investor sectors | All funded startups | All funding rounds |
Click here for a full list of 7,589+ startup investors in the UK